all todays ann really says is that NN does not see it fitting...

all todays ann really says is that NN does not see it fitting into its development program.There could be any number of reasons for that both personal and their view of the drug at this stage.It is still to early to be definitive about it being a dud.Jones spoke of discussions with other pharma so if that was accurate the new Bard will be looking at that.

Reading between the lines from past ann it appears the Co was starting to concentrate on Lupus and this may be the main area of research going forward.It is important we have new management and a vg MD-to be appointed-and then a clearly explained pathway to progress on either the Lupus or a continuation of existing trials on the arthritis.

CBZ is lucky in raising so much recent money at 18c including the placement toZheng He Securities Pty Ltd....the significance of this to be determined. they have about $15m cash -we are now trading at cash.

new Board, $15m cash,lupus etc and poss other pharmas....i would not tell any to buy as not enough info from new Board but at cash its not a sell either esp with a new board intent on making their own mark.